Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa

202194 citationsJournal Articlehybrid Open Access

Authors

B. Alexander Yi

Debra Freedholm

Nancy Widener

Xiaohui Wang · Certara (United States)

Émilie Simard · Certara (United States)

Constance Cullen · Instrumental Polymer Technologies (United States)

Naab Al‐Saady · Covance (United Kingdom)

Norman E. Lepor · Westside Medical Associates of Los Angeles

Abstract

Intravenous and multiple subcutaneous dose administration of abelacimab were safe and well tolerated. The safety, PK, and PD data from these studies support the clinical development of abelacimab.

Topics & Keywords

Coagulation, Bradykinin, Polyphosphates, and Angioedema Vitamin K Research Studies Atrial Fibrillation Management and Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Thrombosis and Haemostasis

Volume 20, Issue 2, pp. 307-315

DOI: 10.1111/jth.15577

Field-Weighted Citation Impact: 8.70